185 related articles for article (PubMed ID: 36585770)
1. Primary resistance to integrase inhibitors in Shenzhen.
Zhu Y; Huang Y; Zheng C; Tang J; Zeng G; Xie W; Wang H; Zhang L; Liu S; Zhang Y; Tan W; Tan J; Jiang L; He Y; Xu L; Yang Z; Zhao J
J Antimicrob Chemother; 2023 Feb; 78(2):546-549. PubMed ID: 36585770
[TBL] [Abstract][Full Text] [Related]
2. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
Cheung PK; Shahid A; Dong W; Lepik KJ; Montaner JSG; Brockman MA; Brumme ZL; Brumme CJ
J Antimicrob Chemother; 2022 Mar; 77(4):979-988. PubMed ID: 35061879
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
[TBL] [Abstract][Full Text] [Related]
4. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection.
Zhao AV; Crutchley RD; Guduru RC; Ton K; Lam T; Min AC
Retrovirology; 2022 Oct; 19(1):22. PubMed ID: 36273165
[TBL] [Abstract][Full Text] [Related]
5. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
[TBL] [Abstract][Full Text] [Related]
6. Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance.
Richetta C; Tu NQ; Delelis O
Viruses; 2022 Nov; 14(12):. PubMed ID: 36560595
[TBL] [Abstract][Full Text] [Related]
7. Integrase Strand Transfer Inhibitor (INSTI) Genotypic Resistance Analysis in Treatment-Naive, INSTI Free Antiretroviral-Experienced and INSTI-Experienced Turkish Patients Infected with HIV-1.
Sayan M; Yildirim FS; Akhan S; Karaoglan I; Akalin H
Curr HIV Res; 2022 Aug; 20(2):184-192. PubMed ID: 35240975
[TBL] [Abstract][Full Text] [Related]
8. Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.
de Salazar A; Viñuela L; Fuentes A; Teyssou E; Charpentier C; Lambert-Niclot S; Serrano-Conde E; Pingarilho M; Fabeni L; De Monte A; Stefic K; Perno CF; Aguilera A; Falces I; Delgado R; Fernandes S; Diogo I; Gomes P; Paraskevis D; Santoro MM; Ceccherini-Silberstein F; Marcelin AG; Garcia F
Clin Infect Dis; 2023 May; 76(9):1628-1635. PubMed ID: 36571282
[TBL] [Abstract][Full Text] [Related]
9. High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.
Ndashimye E; Li Y; Reyes PS; Avino M; Olabode AS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Barr SD; Arts EJ
J Antimicrob Chemother; 2021 Oct; 76(11):2965-2974. PubMed ID: 34453542
[TBL] [Abstract][Full Text] [Related]
10. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S; Charpentier C; Amiel C; Morand-Joubert L; Reigadas S; Trabaud MA; Delaugerre C; Nicot F; Rodallec A; Maillard A; Mirand A; Jeulin H; Montès B; Barin F; Bettinger D; Le Guillou-Guillemette H; Vallet S; Signori-Schmuck A; Descamps D; Calvez V; Flandre P; Marcelin AG;
J Antimicrob Chemother; 2015 May; 70(5):1507-12. PubMed ID: 25558077
[TBL] [Abstract][Full Text] [Related]
11. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
[TBL] [Abstract][Full Text] [Related]
12. Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.
Hachiya A; Kirby KA; Ido Y; Shigemi U; Matsuda M; Okazaki R; Imamura J; Sarafianos SG; Yokomaku Y; Iwatani Y
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28533248
[TBL] [Abstract][Full Text] [Related]
13. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
[TBL] [Abstract][Full Text] [Related]
15. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018-2020).
Yang Z; Yang X; Deng X; Wei S; Liu J; Ma J; Zhao Q; Huo Y
Infection; 2021 Dec; 49(6):1195-1202. PubMed ID: 34279816
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
[TBL] [Abstract][Full Text] [Related]
18. Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir.
Rhee SY; Parkin N; Harrigan PR; Holmes S; Shafer RW
Antiviral Res; 2022 Dec; 208():105427. PubMed ID: 36191692
[TBL] [Abstract][Full Text] [Related]
19. Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study.
Uno S; Gatanaga H; Hayashida T; Imahashi M; Minami R; Koga M; Samukawa S; Watanabe D; Fujii T; Tateyama M; Nakamura H; Matsushita S; Yoshino Y; Endo T; Horiba M; Taniguchi T; Moro H; Igari H; Yoshida S; Teshima T; Nakajima H; Nishizawa M; Yokomaku Y; Iwatani Y; Hachiya A; Kato S; Hasegawa N; Yoshimura K; Sugiura W; Kikuchi T
J Antimicrob Chemother; 2023 Dec; 78(12):2859-2868. PubMed ID: 37856677
[TBL] [Abstract][Full Text] [Related]
20. Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
Cecchini DM; Castillo S; Copertari G; Lacal V; Rodriguez CG; Cassetti I
Rev Esp Quimioter; 2019 Jun; 32(3):263-267. PubMed ID: 31037930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]